DSDmytro Savchenko

Dmytro Savchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmytro Savchenko has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementation of the managed entry agreement framework in Ukraine: a national analysis of the pathway from health technology assessment to concluded agreements

    by Iryna Kostiuk, Zhanna Polova, Kostyantyn Kosyachenko, Dmytro Savchenko

    The aim: to conduct a comprehensive analysis of the implementation of the Managed Entry Agreement (MEA) framework in the public procurement of medicines in Ukraine and to identify the main trends in its development. Materials and methods: a retrospective descriptive study was conducted using official, publicly available national data from the Medical Procurement of Ukraine and the State Expert Center of the Ministry of Health of Ukraine. During the study, a unified database was created that includes medicines under consideration for MEAs as of July 2026. The analysis covered 58 indications corresponding to 48 international non-proprietary names. Methods of content analysis, classification, structural analysis, comparative analysis and summarizing analysis were applied. Data analysis was conducted using descriptive statistics. Results: oncology accounted for the largest share of indications considered for MEAs (31; 53.4%), followed by immunological and other systemic diseases (17; 29.3%) and rare and genetic diseases (10; 17.2%). All included medicines underwent the national Health Technology Assessment (HTA) procedure and received approval to begin negotiations. As of July 2026, MEAs had been signed for 23 indications (39.7%), a negative decision had been recorded for 1 indication (1.7%), and no final decision on conducting an MEA had been recorded for 34 indications (58.6%). Roche had the largest therapeutic portfolio (13 indications), while Takeda and Pfizer were represented in all three therapeutic areas. The number of national HTA recommendations supporting MEA consideration increased from 6 in 2021 to 21 in 2025, indicating a gradual expansion of the MEA framework in Ukraine. Conclusions: the MEA framework is gradually being integrated into the mechanism for public financing of high-cost innovative medicines in Ukraine. National HTA is a key prerequisite for selecting medicines subject to the MEA. For 34 indications (58.6%), no final decision on conducting an MEA had been recorded as of July 2026. The findings provide the first systematic data on the implementation of the Ukrainian MEA framework and may contribute to the further optimization of negotiation procedures, policy development, and improved patient access to innovative medicines

  • Open Access

    Impact of Dosage Form on the Pharmacokinetics, Safety, and Efficacy of Flecainide: a Literature Review

    by Dmytro Savchenko, Zhanna Polova

    With aging, physiological changes occur that affect the pharmacokinetics and pharmacodynamics of drugs. Renal and hepatic impairment, multimorbidity, and polypharmacy increase the risk of adverse reactions in elderly patients. These factors complicate safe drug use and highlight the importance of pharmacovigilance. Flecainide is a class IC antiarrhythmic medication with a narrow therapeutic index. It is frequently used for the treatment of supraventricular arrhythmias. Different dosage forms (immediate-release (IR) and extended-release (ER)) may differently influence blood plasma concentrations, pharmacodynamic effects, and safety, particularly in elderly patients. The objective: to evaluate the impact of flecainide dosage form (IR and ER) on pharmacokinetic parameters, safety outcomes, and efficacy based on published studies. Materials and methods. A narrative review of published clinical and pharmacokinetic studies was conducted, focusing on peak plasma concentration (Cmax), time to reach Cmax (tmax), area under the curve (AUC), elimination half-life (t½), concentration fluctuations, electrocardiographic effects, and safety profiles of medications with IR and ER flecainide formulations. Results. ER formulations are characterized by lower peak concentrations (Cmax), smoother diurnal fluctuations, and a more stable pharmacokinetic profile compared with IR formulations, while providing a comparable systemic exposure. Clinical studies indicate a reduction in peak QRS widening on electrocardiogram with ER administration, suggesting a lower risk of concentration-dependent toxicity. Patients with renal or hepatic failure, chronic heart failure, or carriers of CYP2D6 polymorphic alleles are at increased risk of drug accumulation. Conclusions. ER flecainide formulations reduce blood plasma concentration fluctuations, potentially decreasing peak-related toxicity and providing safer antiarrhythmic therapy, particularly in patients with reduced clearance, including the elderly.

  • Open Access

    Development and Optimization of Nasal Composition of a Neuroprotective Agent for Use in Neonatology after Prenatal Hypoxia

    by Igor Belenichev, Olena Aliyeva, Bogdan Burlaka, Kristina Burlaka, Oleh Kuchkovskyi, Dmytro Savchenko, Valentyn Oksenych, Oleksandr Kamyshnyi

    The intranasal route of drug administration is characterized by high bioavailability and is considered promising for rapid delivery of drugs with systemic action to the central nervous system (CNS), bypassing the blood-brain barrier. This is particularly important for the use of neuroprotective drugs in the treatment of brain tissue damage in infants caused by the effects of intrauterine hypoxia. The creation of new dosage forms for neonatology using mathematical technologies and special software in pharmaceutical development allows for the creation of cerebroprotective drugs with controlled pharmaco-technological properties, thus reducing time and resources for necessary research. We developed a new nasal gel formulation with Angiolin using a Box-Behnken experiment design for the therapy of prenatal CNS damage. It was found that the consistency characteristics of the nasal gel were significantly influenced by the gelling agent and mucoadhesive component—sodium salt of carboxymethylcellulose. We optimized the composition of nasal gel formulation with Angiolin using the formed models and relationships between the factors. The optimized nasal gel composition demonstrated satisfactory thixotropic properties. The 1% gel for neuroprotection with Angiolin, developed for intranasal administration, meets all safety requirements for this group of drug forms, showing low toxicity and no local irritant or allergic effects.


  • Open Access

    Development and optimization of nasal composition of a neuroprotective agent for use in neonatology after prenatal hypoxia

    by Igor Belenichev, Olena Aliyeva, Bogdan Burlaka, Kristina Burlaka, Oleh Kuchkovskyi, Dmytrо Savchenko, Valentyn Oksenych, Oleksands Kamyshnyi

    The intranasal route of drug administration is characterized by high bioavailability and is considered promising for rapid delivery of drugs with systemic action to the central nervous system, bypassing the blood-brain barrier. This is particularly important for the use of neuroprotective drugs in the treatment of brain tissue damage in infants caused by the effects of intrauterine hypoxia. Creation of new dosage forms for neonatology with the use of software and mathematical technologies in pharmaceutical development allows to create cerebroprotective drugs with controlled pharmaco-technological properties, thus reducing time and resources for necessary research. We developed a formulation of a new nasal gel formulation with Angiolin using Box-Benken experiment design for the therapy of prenatal CNS damage. It was found that the consistency properties of the nasal gel were significantly influenced by the gelling agent and mucoadhesive component - sodium salt of carboxymethylcellulose. We have optimized the composition of nasal gel formulation with Angiolin using the formed models and relationships between the factors. The optimized composition of the obtained nasal gel has satisfactory parameters of thixotropic properties. The developed 1% gel for neuroprotection with Angiolin meets all the requirements for harmlessness and safety to drug forms of this group - low toxicity, absence of local irritant and allergic effect.


  • Open Access

    Modulating Nitric Oxide: Implications for Cytotoxicity and Cytoprotection

    by Igor Belenichev, Olena Popazova, Nina Bukhtiyarova, Dmytro Savchenko, Valentyn Oksenych, Oleksandr Kamyshnyi

    Despite the significant progress in the fields of biology, physiology, molecular medicine, and pharmacology; the designation of the properties of nitrogen monoxide in the regulation of life-supporting functions of the organism; and numerous works devoted to this molecule, there are still many open questions in this field. It is widely accepted that nitric oxide (•NO) is a unique molecule that, despite its extremely simple structure, has a wide range of functions in the body, including the cardiovascular system, the central nervous system (CNS), reproduction, the endocrine system, respiration, digestion, etc. Here, we systematize the properties of •NO, contributing in conditions of physiological norms, as well as in various pathological processes, to the mechanisms of cytoprotection and cytodestruction. Current experimental and clinical studies are contradictory in describing the role of •NO in the pathogenesis of many diseases of the cardiovascular system and CNS. We describe the mechanisms of cytoprotective action of •NO associated with the regulation of the expression of antiapoptotic and chaperone proteins and the regulation of mitochondrial function. The most prominent mechanisms of cytodestruction—the initiation of nitrosative and oxidative stresses, the production of reactive oxygen and nitrogen species, and participation in apoptosis and mitosis. The role of •NO in the formation of endothelial and mitochondrial dysfunction is also considered. Moreover, we focus on the various ways of pharmacological modulation in the nitroxidergic system that allow for a decrease in the cytodestructive mechanisms of •NO and increase cytoprotective ones.


  • Open Access

    Nitric Oxide in the Mechanisms of Cell Death and Cytoprotection

    by Igor Belenichev, Olena Popazova, Nina Bukhtiyarova, Dmytro Savchenko, Valentyn Oksenych, Oleksandr Kamyshnyi

    The regulation of cell death is a fundamental issue in cell biology and continues to be intensely investigated worldwide. The significance of research in this field persists because understanding the determinants of cell lifespan directly impacts the maintenance of multicellular organism homeostasis and, consequently, is crucial for addressing biomedical challenges associated with various diseases. It is recognized that the initiation of cell death can be prompted by both specific signals (such as cytokines or hormones) and nonspecific stimuli, including radiation, temperature increase, or oxidants. When these factors affect a cell, numerous signaling pathways are triggered in the cell, leading to neutralization of the effects of their negative effects or, in case of irreparable damage, to cell elimination. This removal of damaged cells occurs through apoptosis or programmed cell death, a highly regulated process. Numerous signaling molecules participate in orchestrating the apoptotic process, many of which also govern other essential functions within the organism. Physiological factors capable of triggering the apoptotic program in cells include nitric oxide (NO), which serves as one of the key signaling molecules regulating the functions of the cardiovascular, nervous, and immune systems of the organism. The unique chemical nature of NO, along with its numerous intracellular targets and physiologically active redox forms, raises questions about the specific mechanisms through which NO exerts its damaging effects on cells. Utilizing pharmacological preparations- such as sources (donors) of exogenous nitric oxide- represents an approach to investigating the initiation and execution of the apoptotic program in sensitive target cells. Furthermore, this approach holds promise as a direction for discovering new selective drugs.